MPM Oncology Impact Management »

Agios Pharmaceuticals shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Agios Pharmaceuticals (AGIO) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Agios Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Agios Pharmaceuticals held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Agios Pharmaceuticals by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $36M 1.3M 27.22

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Madrigal Pharmaceuticals Common (MDGL)
Liquidia Corp Common (LQDA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Uniqure NV Common (QURE)
PTC Therapeutics Common (PTCT)
Syndax Pharmaceuticals Common (SNDX)
Dyne Therapeutics Common (DYN)
Tarsus Pharmaceuticals Common (TARS)
Stoke Therapeutics Common (STOK)
Alumis Common (ALMS)
Urogen Pharma Common (URGN)

View all positions for MPM Oncology Impact Management

Top funds holding Agios Pharmaceuticals

Vanguard Group
Farallon Capital Management
BlackRock
State Street Corporation
Susquehanna International
Paradigm Biocapital Advisors
Erste Asset Management GmbH
Wellington Management Company
Armistice Capital
Jane Street
TCG Crossover Management
Geode Capital Management
Bnp Paribas Investment Partners
MPM Oncology Impact Management
Frazier Life Sciences Management

View all funds holding Agios Pharmaceuticals